- Home
- SCNX vs SABS Comparison
SCNX vs SABS Comparison
Compare SCNX & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- SABS
- Stock Information
- Founded
- SCNX 2010
- SABS 2014
- Country
- SCNX United States
- SABS United States
- Employees
- SCNX N/A
- SABS N/A
- Industry
- SCNX Other Pharmaceuticals
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- SABS Health Care
- Exchange
- SCNX Nasdaq
- SABS Nasdaq
- Market Cap
- SCNX 14.4M
- SABS 15.8M
- IPO Year
- SCNX 2020
- SABS N/A
- Fundamental
- Price
- SCNX $0.98
- SABS $1.74
- Analyst Decision
- SCNX
- SABS Strong Buy
- Analyst Count
- SCNX 0
- SABS 5
- Target Price
- SCNX N/A
- SABS $11.80
- AVG Volume (30 Days)
- SCNX 129.8K
- SABS 17.6K
- Earning Date
- SCNX 08-10-2025
- SABS 08-07-2025
- Dividend Yield
- SCNX N/A
- SABS N/A
- EPS Growth
- SCNX N/A
- SABS N/A
- EPS
- SCNX N/A
- SABS N/A
- Revenue
- SCNX $146,901.00
- SABS $377,835.00
- Revenue This Year
- SCNX N/A
- SABS N/A
- Revenue Next Year
- SCNX N/A
- SABS N/A
- P/E Ratio
- SCNX N/A
- SABS N/A
- Revenue Growth
- SCNX N/A
- SABS N/A
- 52 Week Low
- SCNX $0.69
- SABS $1.00
- 52 Week High
- SCNX $23.77
- SABS $5.01
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- SABS 49.33
- Support Level
- SCNX N/A
- SABS $1.60
- Resistance Level
- SCNX N/A
- SABS $1.87
- Average True Range (ATR)
- SCNX 0.00
- SABS 0.11
- MACD
- SCNX 0.00
- SABS -0.01
- Stochastic Oscillator
- SCNX 0.00
- SABS 62.07
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.